Committed to the Future of Antibiotics

News
9 June 2017

Meet Da Volterra at BIO2017 in San Diego

Our CEO, Florence Séjourné, is pleased to speak (...)

15 May 2017

Da Volterra Presenting Protection of the Intestinal Microbiota at ASM Microbe 2017

Da Volterra is excited to give an Oral Presentation at ASM (...)

11 April 2017

Da Volterra Anticipating an Invigorating ECCMID 2017

ECCMID 2017 in Vienna, Austria is rapidly approaching the (...)

8 March 2017

Da Volterra's CSO will present a webinar: Antibiotics & the Microbiome March 9th

Our CSO, Jean de Gunzburg will present a free webinar in (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >

 

Developpeur PHP Drupal